Holen Sie sich die Stockscreener-App
157.12
0.23%
-0.37
Handel nachbörslich:
157.12
Schlusskurs vom Vortag:
$157.49
Offen:
$158.08
24-Stunden-Volumen:
247.09K
Relative Volume:
0.16
Marktkapitalisierung:
$7.42B
Einnahmen:
$4.06B
Nettoeinkommen (Verlust:
$413.08M
KGV:
19.62
EPS:
8.01
Netto-Cashflow:
$560.48M
1W Leistung:
+3.65%
1M Leistung:
+13.45%
6M Leistung:
-15.44%
1J Leistung:
-21.99%
1-Tages-Spanne:
$156.17
$158.72
1-Wochen-Bereich:
$148.41
$160.40
52-Wochen-Spanne:
$91.86
$254.15
Charles River Laboratories International Inc Stock (CRL) Company Profile
Firmenname
Charles River Laboratories International Inc
Sektor
Branche
Telefon
781-222-6000
Adresse
251 BALLARDVALE ST, WILMINGTON, MA
Vergleichen Sie CRL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
157.12 | 7.42B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
429.33 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
203.20 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
547.01 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
121.38 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
164.24 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-23 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2025-05-08 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-03-21 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-03 | Hochstufung | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | Herabstufung | UBS | Buy → Neutral |
| 2024-11-18 | Herabstufung | CLSA | Hold → Underperform |
| 2024-11-07 | Hochstufung | CLSA | Underperform → Hold |
| 2024-10-23 | Eingeleitet | CLSA | Underperform |
| 2024-10-14 | Eingeleitet | Redburn Atlantic | Sell |
| 2024-10-07 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-10-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-01 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-08 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Herabstufung | Argus | Buy → Hold |
| 2024-06-07 | Eingeleitet | Mizuho | Neutral |
| 2024-06-06 | Eingeleitet | Goldman | Buy |
| 2024-02-15 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-09-13 | Eingeleitet | TD Cowen | Market Perform |
| 2023-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-02-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-01-12 | Herabstufung | Jefferies | Buy → Hold |
| 2022-09-30 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-04 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | Eingeleitet | Guggenheim | Neutral |
| 2022-04-25 | Herabstufung | Jefferies | Buy → Hold |
| 2022-04-07 | Eingeleitet | Stephens | Overweight |
| 2022-02-17 | Bestätigt | BofA Securities | Buy |
| 2022-02-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-02-17 | Bestätigt | Deutsche Bank | Buy |
| 2022-02-17 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-17 | Bestätigt | UBS | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2020-12-16 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-10 | Hochstufung | Jefferies | Hold → Buy |
| 2020-07-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-05-13 | Hochstufung | UBS | Neutral → Buy |
| 2020-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | Eingeleitet | Deutsche Bank | Buy |
| 2020-02-18 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | Hochstufung | Goldman | Neutral → Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-18 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-30 | Fortgesetzt | Evercore ISI | Outperform |
| 2018-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-09 | Eingeleitet | UBS | Neutral |
| 2018-08-23 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Charles River Laboratories International Inc Aktie (CRL) Neueste Nachrichten
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment | CRL Stock News - GuruFocus
Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment - Business Wire
Do Wall Street Analysts Like Charles River Laboratories Stock? - MSN
Global Viral Inactivation Market | Solvent Detergent & - openPR.com
Charles River falls after projecting 2025 revenue drop - MSN
Medical Device Testing Market Trends | Regulatory Compliance - openPR.com
Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q4 2024 Earnings Call Transcript - MSN
Charles River surges after Q1 beat, guidance raise - MSN
FDA’s Intent To Phase Out Animal Testing Requirement Weighs Down Charles River Stock: Retail’s Disheartened - MSN
Insiders At Charles River Laboratories International Sold US$2.8m In Stock, Alluding To Potential Weakness - simplywall.st
Rhumbline Advisers Increases Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Transcript : Charles River Laboratories International, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener
Polen U.S SMID Company Growth Strategy Sold Charles River Laboratories International (CRL) for More Attractive Opportunities - Insider Monkey
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report? - Yahoo Finance
Regulatory Affairs Outsourcing Market Analysis Report 2025: Globalization of Biopharmaceutical and Medical Device Companies Bolster Growth - GlobeNewswire Inc.
William Blair Remains a Hold on Charles River Labs (CRL) - The Globe and Mail
Charles River at Jefferies Conference: Strategic Moves Amid Challenges By Investing.com - Investing.com Canada
Transcript : Charles River Laboratories International, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 10 - marketscreener.com
Charles River Laboratories To Present At Jefferies Global Conference; Webcast At 10:30 AM ET - Nasdaq
Cell Banking Outsourcing Market To Witness Substantial Growth, - openPR.com
Charles River Stock May Gain From Extended CHDI Research Deal on HD - MSN
Charles River Laboratories International Inc (CRL) Shares Up 3.0 - GuruFocus
Charles River at William Blair Conference: Navigating Challenges with Innovation - Investing.com Australia
Charles River Laboratories To Present At William Blair Growth Stock Conference; Webcast At 11:00 AM - Nasdaq
Charles River Laboratories to Present at William Blair and Jefferies Conferences - BioSpace
Charles River Laboratories to Present at William Blair and Jeffe - GuruFocus
Charles River Laboratories to Present at William Blair and Jefferies Conferences | CRL Stock News - GuruFocus
Charles River Laboratories International, Inc. (CRL): A Bull Case Theory - Insider Monkey
Charles River Laboratories, CHDI Foundation Extend Collaboration - marketscreener.com
Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - BioSpace
Charles River Laboratories International Extend Drug Discovery Partnership With CHDI Foundation - marketscreener.com
Charles River Labs extends Huntington’s disease research pact By Investing.com - Investing.com India
Charles River (CRL) and CHDI Foundation Extend Partnership for H - GuruFocus
Charles River Labs extends Huntington’s disease research pact - Investing.com Australia
Charles River (CRL) and CHDI Foundation Extend Partnership for Huntington's Drug Discovery | CRL Stock News - GuruFocus
Charles River Laboratories (CRL) and CHDI Foundation Extend Multi-Decade Collaboration on Huntington’s Disease Research - StreetInsider
Redburn Upgrades Charles River Laboratories (CRL) to Buy, Cuts PT - MSN
Should You Continue to Hold Charles River Stock in Your Portfolio? - MSN
There's No Escaping Charles River Laboratories International, Inc.'s (NYSE:CRL) Muted Revenues Despite A 25% Share Price Rise - simplywall.st
Charles River Laboratories International, Inc. (CRL) Extends CEO's Employment Agreement - GuruFocus
Charles River (CRL) Upgraded to Buy Amid Strategic Developments | CRL Stock News - GuruFocus
Redburn raises Charles River Labs to buy, cuts price target to $182 - Investing.com Nigeria
Redburn raises Charles River Labs to buy, cuts price target to $182 By Investing.com - Investing.com South Africa
Charles River Laboratories International CEO James C. Foster's Employment Extended Until February 2027SEC Filing - marketscreener.com
Finanzdaten der Charles River Laboratories International Inc-Aktie (CRL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Charles River Laboratories International Inc-Aktie (CRL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MASSARO GEORGE | Director |
May 15 '25 |
Sale |
137.57 |
140 |
19,260 |
5,575 |
| MASSARO GEORGE | Director |
May 14 '25 |
Sale |
140.73 |
140 |
19,703 |
5,715 |
| LaPlume Joseph W | EVP, Corp Strategy & Develop |
May 13 '25 |
Sale |
145.41 |
500 |
72,705 |
19,513 |
0.18%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):